Clinical trial
Immuno-consolidation for Newly Diagnosed Multiple Myeloma Using Lack of MRD Negativity After Initial cOmbination Therapy to Pursue Deeper Responses With Linvoseltamab ANd Delay Transplant
NCT06376526 is registered in ClinicalTrials.gov with Dickran Kazandjian, MD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immuno-consolidation for Newly Diagnosed Multiple Myeloma Using Lack of MRD Negativity After Initial cOmbination Therapy to Pursue Deeper Responses With Linvoseltamab ANd Delay Transplant
- Lead sponsor
- Dickran Kazandjian, MD
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 21, 2024
- Completion date
- August 31, 2029
- Enrollment
- 150 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.